🫁 Pneumococcal (Pneumonia) Vaccines
3 major studies graded on 9 RCT methodology criteria.
Pneumococcal vaccines prevent bacterial pneumonia caused by Streptococcus pneumoniae. Multiple formulations exist: PPSV23 (Pneumovax, decades of use), PCV13 (Prevnar 13), PCV15, and PCV20. The evidence base is extensive — including the CAPITA trial, one of the largest vaccine RCTs ever — but dominated by manufacturer funding.
🧪 What do these 9 criteria mean? click to expand
A comparison group received a different treatment (or no treatment) under identical conditions.
Without a control group, you cannot determine whether changes in outcomes were caused by the vaccine or other factors.
Participants were randomly assigned to vaccine or control — not by age, risk, or researcher choice.
Randomization prevents selection bias, ensuring the vaccinated and unvaccinated groups are comparable at baseline.
Neither participants nor researchers measuring outcomes knew who received the vaccine.
Blinding prevents both reporting bias (participants feeling better just from getting a shot) and measurement bias.
The control group received an inert substance (saline) — not another active vaccine.
Active comparators can mask safety signals. If the control group also experiences side effects, adverse events in the test group may appear deceptively normal.
At least 1,000 participants were enrolled.
Larger samples detect modest effects and rare adverse events. A 200-person study might miss a side effect affecting 1 in 500.
Participants were tracked for at least one year after vaccination.
Short follow-up windows miss delayed adverse events, waning immunity, and long-term effectiveness.
Funded primarily by government, universities, or non-profits — not the manufacturer.
Industry-funded trials are statistically more likely to show positive results for the funder's product. This is a documented pattern, not an accusation.
Published in a peer-reviewed journal after independent scientific review.
Peer review catches methodological errors, though it is not a guarantee of correctness.
Independent researchers or real-world surveillance data confirmed the core findings.
Single trials can contain errors. When multiple independent studies find similar results, confidence increases substantially.
Study Summary
One of the largest vaccine RCTs ever conducted. Enrolled 84,496 adults aged 65+ in the Netherlands over 4 years. Found PCV13 was 45.6% effective against vaccine-type community-acquired pneumonia and 75% effective against vaccine-type invasive pneumococcal disease.
Strengths
Exceptional sample size (84,496) and 4-year follow-up. Saline placebo, double-blind, randomized. Confirmed by UK and US surveillance data.
Limitations
Funded by Pfizer with Pfizer employees involved in study conduct. Conducted in the Netherlands, where children's PCV vaccination had already reduced circulating strains — limiting US generalizability. ACIP later revised recommendations partly due to this population-level herd effect.
Study Summary
Systematic review of 25 randomized trials of PPSV23 (the older 23-valent polysaccharide vaccine). Found robust evidence for protection against invasive pneumococcal disease (IPD) in adults — serotype-specific protection ~74%. Evidence for all-cause pneumonia protection was less consistent.
Strengths
Independently funded. Pooled 25 RCTs. Transparent about heterogeneity and limitations. Widely cited by ACIP and international vaccine advisory committees.
Limitations
PPSV23 does not produce immunological memory (T-cell independent response), explaining inconsistent protection against non-bacteremic pneumonia. Evidence in immunocompromised adults was sparse. Some included trials were older with variable quality.
Study Summary
Phase 3 immunogenicity trial of PCV20 in 4,957 adults aged 60+, using PCV13 as an active comparator (not saline placebo). Demonstrated non-inferior immune responses for shared serotypes and superior responses for 7 new ones. FDA approval was based on immune response data — no clinical efficacy trial (preventing actual pneumonia) was required.
Strengths
Large, randomized, double-blind. Compared to existing standard of care. PCV20 covers more serotypes than predecessors.
Limitations
No saline placebo — active comparator (PCV13) used. Primary endpoint was immune response (antibody levels) at 1 month, not actual pneumonia prevention. Approval via immune bridging is a lower bar than a clinical efficacy trial. Entirely Pfizer-funded. Limited long-term data.
📋 What This Means
The CAPITA trial for PCV13 was a methodological standout: 84,496 adults, four-year follow-up. The Cochrane review of PPSV23 found strong evidence for protection against invasive pneumococcal disease. The newer PCV20 approval was based on immune response data rather than demonstrated disease prevention in a placebo-controlled trial — a meaningful distinction.